AZN AstraZeneca PLC
Company Analysis
Latest News
🟢 AstraZeneca is trading 3.02% up today after positive Tagrisso and Enhertu lung-cancer results
AstraZeneca is trading 3.02% up at $164.93 after positive Phase III results for Tagrisso plus savolitinib and Enhertu in non-small-cell lung cancer. -...
AstraZeneca Halts Volrustomig Lung Cancer Trial, Threatening Revenue Targets
AstraZeneca terminated its Phase III eVOLVE-Lung02 clinical trial for volrustomig combined with chemotherapy. The study evaluated the regimen as a first-line...
AstraZeneca beats standard care, hitting first-line lung cancer milestone with Enhertu
AstraZeneca and Daiichi Sankyo announced that Enhertu met its primary endpoint in the DESTINY-Lung04 Phase III trial. The study evaluated Enhertu as a...
AstraZeneca PLC Q2 2026 Earnings Preview: What Analysts Expect on July 27, 2026
Consensus estimates for Q2 2026 project revenue at $15.45 billion and earnings at $2.50 per share, as the current stock price of $169.26 trades significantly...
Healthcare Movers: Key Drug Approvals and Corporate Updates
The healthcare sector saw key regulatory and corporate news this week. AstraZeneca received U.S. FDA approval for Baxfendy, a first-in-class drug for...
AstraZeneca PLC Q1 2026 Earnings Preview: What Analysts Expect on April 29, 2026
AstraZeneca is projected to report Q1 2026 revenue of $14.98 billion and core EPS of $2.57, with its current stock price of $189.71 trading below the average...